Siblings Books/Book Section [1/1] Periodical Articles [327/330] Collection Statistics Item counts issued in 3 years:16(8.94%) Items With Fulltext:115(64.25%) Download counts of the item Download times greater than 0:115(100.00%) Download times greater than 100:112(97.39%) Total Bitstream Download Counts:39103(22.05%) Last Update: 2024-11-28 17:59 Top Upload Loading... Top Download Loading... Recent Submissions Single-cell RNA sequencing via Endo... Nivolumab plus ipilimumab (N plus I... Risk of type 2 diabetes mellitus an... Phase 1 studies of D07001-F4 and D0... Updated overall survival (OS) from ... Outcomes of post-immunotherapy dura... Updated overall survival (OS) from ... Updated results of the FOENIX-CCA2 ... Comparative genomic analysis and it... A phase II trial of nivolumab, gemc...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 91-100 of 179. (18 Page(s) Totally) << < 5 6 7 8 9 10 11 12 13 14 > >> View [10|25|50] records per page

Date	Title	Relation
2016-10	Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther	Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 693P.
2016-10	CagA and NFAT co-operatively participate in the lymphomagenesis of gastric MALT lymphoma	Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 933P.
2016-09	Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: Results from t	Annals of Oncology. 2016 Sep;27(Suppl. 4):Meeting Abstract B04.
2016-06	Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study	Annals of Oncology. 2016 Jun;27(Suppl. 2):ii84.
2016-06	Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine	Annals of Oncology. 2016 Jun;27(Suppl. 2):119.
2016-06	Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2016 Jun;27(Suppl. 2):110.
2016-05	Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine	Journal of Clinical Oncology. 2016 May;34(15, Suppl.):Meeting Abstract 4126.
2016-05	Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15740.
2016-05	Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number 4017.
2016-05	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15732.

Showing items 91-100 of 179. (18 Page(s) Totally) << < 5 6 7 8 9 10 11 12 13 14 > >> View [10|25|50] records per page